No GVK Bioscience trialled drugs under EMA spotlight are sold in Switzerland says Swissmedic

By Gareth Macdonald contact

- Last updated on GMT

Swissmedic HQ in Bern - no GVK trialled drugs listed in EMA probe sold in Switzerland
Swissmedic HQ in Bern - no GVK trialled drugs listed in EMA probe sold in Switzerland

Related tags: European union, Switzerland

None of the drugs the EMA wants suspended over concerns about data manipulation at GVK Biosciences are sold in Switzerland says Swissmedic.

The Swiss regulator made the announcement last week after a review prompted by the European Medicines Agency’s (EMA) recommendation​ that hundreds of drugs​ trialled at a GVK site in Hyderabad, India be suspended.

Swissmedic said none of the drugs on the EMA list are sold in the country, although “three preparations with export authorisations were identified.​” The organisation explained that these authorisations are granted for drugs not distributed in Switzerland, but intended exclusively for export.

“After the irregularities were disclosed, Swissmedic initially examined the authorisations granted for generics in Switzerland on the basis of studies by the company GVK Biosciences.

Swissmedic added that: "Around 250 authorisations were checked using active substance lists published by the German Federal Institute for Drugs and Medical Devices (BfArM) and the French National Agency for Medicines and Health Products Safety (ANSM).​”

Norway, Iceland and Switzerland

The Bern-based regulator also said it had checked a further 350 drugs that had been approved in the European Union and Norway and Iceland – which like Switzerland are not in the EU – on the basis of defective GVK bioequivalence studies.

The comprehensive analysis revealed that no corresponding preparations are available on the Swiss market. However, Swissmedic did find three products that have been authorised for distribution abroad.

It added that: “The affected companies have been asked to issue statements on the available documentation. Swissmedic will then take the required measures and, if necessary, suspend or withdraw the authorisations.”

The EMA’s proposal has been sent to the European Commission for the final decision which, if in agreement with the recommendation, will apply to all Member States irrespective of whether or not they have taken interim measures to suspend medicines.

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Related suppliers

Follow us

Featured Events

View more

Products

View more